NORTH PALM BEACH, Fla. — August 4, 2026 — Leads & Copy — SRX Global Inc., an AI-enabled platform focused on generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, announced today its acquisition of a stake in Vistagen Therapeutics, Inc. (Vistagen). Vistagen is a late clinical-stage biopharmaceutical company specializing in neuroscience, utilizing nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates known as pherines.
SRX Global considers Vistagen shares to be undervalued and has expressed a desire for constructive engagement with Vistagen’s leadership team and Board of Directors. The objective of this engagement is to discuss strategies for unlocking shareholder value.
SRX Global operates as an AI-driven platform dedicated to creating long-term shareholder value. Its investment strategy centers on high-conviction operating companies, strategic assets, and technology-enabled opportunities. The company employs proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across various sectors.
Source: SRX Global Inc.
